Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Peritoneal Cell-Free Tumor DNA is a Biomarker of Locoregional and Peritoneal Recurrence in Resected Pancreatic Ductal Adenocarcinomas.

Annals of surgical oncology - 1 Oct 2023

Leick Katie M, Tomanek-Chalkley Ann, Coleman Kristen L, Chan Carlos H F

Abstract excerpt

BACKGROUND: Recurrence after curative-intent pancreatectomy for pancreatic ductal adenocarcinomas (PDAC) is quite frequent with locoregional and peritoneal recurrence in about one-third of cases. We hypothesize that peritoneal cell-free tumor DNA (ptDNA) present in the intraoperative peritoneal lavage (PL) fluid may be used as a predictive biomarker of locoregional and peritoneal recurrence. PATIENTS AND METHODS:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Carcinoma, Pancreatic Ductal

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Circulating Tumor DNA

Share to Neoplasm Recurrence, Local

Share to Pancreatic Neoplasms

Share to Peritoneal Neoplasms

Share to Prognosis

Share to Proto-Oncogene Proteins p21(ras)

Source

Identifiers

PMID: 37303025
DOI: 10.1245/s10434-023-13701-2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Peritoneal Cell-Free Tumor DNA is a Biomarker of Locoregional and Peritoneal Recurrence in Resected Pancreatic Ductal Adenocarcinomas.PMID 37303025Read ↗

Prognostic impact of postoperative circulating tumor DNA as a molecular minimal residual disease marker in patients with pancreatic cancer undergoing surgical resection.Semantic proximity Read ↗

Clinical Implications of Pre- and Postoperative Circulating Tumor DNA in Patients with Resected Pancreatic Ductal Adenocarcinoma.Semantic proximity Read ↗

Plasma KRAS mutations predict the early recurrence after surgical resection of pancreatic cancer.Semantic proximity Read ↗

Prognostic value of circulating tumour DNA in patients undergoing curative resection for pancreatic cancer.Semantic proximity Read ↗

Circulating tumor DNA correlates with tumor burden and predicts outcome in pancreatic cancer irrespective of tumor stage.Semantic proximity Read ↗

Preoperative detection of KRAS G12D mutation in ctDNA is a powerful predictor for early recurrence of resectable PDAC patients.Semantic proximity Read ↗

Predicting disease recurrence in pancreatic ductal adenocarcinomaSemantic proximity Read ↗

Molecular Alterations Associated with DNA Repair in Pancreatic Adenocarcinoma Are Associated with Sites of Recurrence.Semantic proximity Read ↗

Unexpected Long-Term Survival in Resected Pancreatic Ductal Adenocarcinoma Harboring KRAS G12D/SMAD4 Co-Mutation: A Case Report and Mini-ReviewSemantic proximity Read ↗

Genomic and Molecular Analyses Identify Molecular Subtypes of Pancreatic Cancer RecurrenceSemantic proximity Read ↗

Mutant KRAS in Circulating Tumor DNA as a Biomarker in Localized Pancreatic Cancer Patients Treated With Neoadjuvant Chemotherapy.Semantic proximity Read ↗

Molecular diagnosis for detecting KRAS mutation in peritoneal washing fluid of pancreatic ductal adenocarcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.